Life Science Investing neffy® Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions
Life Science Investing UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Life Science Investing ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
Life Science Investing ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Life Science Investing ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy®
Life Science Investing ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
Life Science Investing neffy® Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions
Life Science Investing Real-World Evidence Supports Clinical Effectiveness of neffy® in Patients Experiencing Anaphylaxis
Life Science Investing ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy®
RZOLV Technologies Announces Independent SGS Lab-Scale Test Results on Gravity Concentrates - 98.7% Gold Recoveries
RZOLV Technologies Announces Independent SGS Lab-Scale Test Results on Gravity Concentrates - 98.7% Gold Recoveries
NextSource Materials Executes Term Sheets with Strategic Investors and Local Capital Partners to Advance Towards Final Investment Decision for its Proposed UAE Battery Anode Facility
